Business Wire

NielsenIQ Sets the Pace for the Omnichannel Measurement Revolution

28.9.2021 15:00:00 EEST | Business Wire | Press release

Share

NielsenIQ, the industry leader in global measurement and data analytics, announced today two key acquisition agreements --Data Impact and Rakuten Intelligence. These acquisitions will drive significant value to NielsenIQ’s e-commerce and omnichannel measurement solutions and allow the company to revolutionize the consumer and retail measurement industries with a comprehensive view of the online marketplace, from product distribution to sales.

Today, e-commerce sales account for 12% of CPG sales in the U.S. and up to 30% of sales in global markets and are estimated to grow at a 15% CAGR through 2025. With significant growth and share from online-focused retailers, it has become more important to understand the total marketplace. Nevertheless, current e-commerce measurement is highly fragmented, with multiple, disparate offerings that do not allow an integrated and consistent view of the total market.

These acquisitions and suite of omnichannel measurement solutions uniquely position NielsenIQ to provide retailers and manufacturers with a harmonized, granular, and consistent view across channels, allowing them to anticipate trends, understand, and react faster to consumer needs and expectations.

“Measuring e-commerce is a top strategic imperative for NielsenIQ,” said Natalie Williams, Head of North America Measurement Product Leadership, NielsenIQ. “Together we can transform the way we measure e-commerce sales and how fast the shopper journey evolves by delivering powerful machine learning-driven insights to our clients around the world.”

The agreement to acquire Data Impact, a leading e-commerce intelligence player in 40 markets mainly across Europe and the U.S., will supercharge NielsenIQ’s omnichannel service. Combining Data Impact’s best-in-class technology - which provides a hypergranular view of banner and store-level e-commerce insights - with NielsenIQ’s unmatched retail measurement footprint, will enable NielsenIQ to scale Data Impact’s product offering globally; and most importantly, will position NielsenIQ to lead the future of omnichannel measurement and execution.

“Combining our technology with Data Impact’s unique offering enables us to offer manufacturers and retailers unparalleled, comprehensive coverage with the granularity needed to make winning omnichannel decisions,” said Jim Peck, Executive Chairman and CEO of NielsenIQ.

The acquisition of Rakuten Intelligence, three years after signing an exclusive agreement to combine Rakuten Intelligence’s largest e-commerce purchase panel in the U.S. with NielsenIQ’s retail sales data, will allow NielsenIQ to deliver our clients an integrated online and offline read, aligned to custom client hierarchies, underpinned by our cloud-based Connect platform. NielsenIQ’s recently launched Omnisales product is the first integration derived from this acquisition.

“We are proud to welcome these two champions into the NielsenIQ family. We will be able to provide a single number for online sales measurement through multi-sourced data - the truth the market needs - and we will also deliver e-commerce execution recommendations with unrivaled actionability. With unique scale and granularity, the landscape of opportunities is unlimited,” mentioned Clément Colin, Head of International E-commerce Measurement, NielsenIQ.

About NielsenIQ

NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.

Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.

NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com.

About Data Impact

Data Impact is one of the cutting-edge providers in omnichannel analytics solutions. The company uses localized data and AI algorithms to offer its customers various solutions, including location-based analytics, sales and shares estimates, media monitoring, SEO optimization, and more.

The Data Impact solution is already used by more than 150 companies in more than 40 countries. Launched in 2016, Data Impact is the only solution that offers FMCG manufacturers a precise visualization of their omnichannel distribution and the ability to identify localized levers of action.

About Rakuten Intelligence

Rakuten Intelligence is part of Rakuten Advertising, which connects leading agencies, brands and publishers to active and engaged consumers around the world. With access to Rakuten’s diverse media properties and audiences, combined with an award-winning performance network and proprietary consumer research, Rakuten Advertising creates the right conditions to reach new customers and sustain long-lasting loyalty.

Its foundation of advanced technology, data, and strategic services positions Rakuten Advertising to offer a differentiated suite of marketing and advertising solutions while continually pushing the industry forward. It is a division of Rakuten Inc., one of the world’s leading Internet service companies. The company is headquartered in San Mateo, CA, with offices throughout EMEA, APAC, LATAM, and North America. Learn more at www.rakutenadvertising.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
(U.S. and English)
FERNANDA PAREDES, fernanda.paredes@nielseniq.com, +1-917-291-1196
GILLIAN MOSHER, gillian.mosher@nielseniq.com, +1-647-282-9714
(France) SEBASTIEN MONARD, sebastien.monard@nielseniq.com, +33-6-85-32-94-61

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye